{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T04:08:03Z","timestamp":1779077283960,"version":"3.51.4"},"reference-count":138,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":110,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Friedreich\u2019s Ataxia (FRDA) is a progressive disorder, which is autosomal recessive. It is one of the most common inherited ataxias in Europe, the Middle East, South Asia and North Africa. It is a life limiting condition, the time of onset until death is on average 36 years. A lack of certainty about specific phenotypic changes, has meant that, until recently, there have been no medications licensed for use in FRDA. Over the last 5 years, the development of omaveloxolone has stimulated increasing research into the mechanistic understanding of FRDA. We have conducted a critical review of all the studies published between 1999 and December 2024. The free text search terms were ((Friedreich\u2019s Ataxia) OR (FRDA) OR (FRDA) OR (inherited ataxias)) AND ((recent developments) OR (new developments) OR (new treatments) OR (phenotype)). We identified common themes, for example cellular phenotypical changes, such as mitochondrial and iron dysregulation and common medications that have been trialled. We have analysed the relevant, available studies (n = 139), highlighting the underlying reasons for any reported discrepancies. The papers in this review demonstrate what we know about the frataxin deficiency, which causes mitochondrial dysfunction and iron dysregulation. We also discuss what is not known and how these gaps in knowledge can affect the development of new therapeutic approaches. We investigate the cellular phenotypical changes in FRDA that are either established or hypothesized in the current literature, review the medications that have been tested and their trial outcomes, and consider potential future approaches that could guide the development of new therapies for FRDA.<\/jats:p>","DOI":"10.1093\/braincomms\/fcag143","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T11:15:23Z","timestamp":1776510923000},"source":"Crossref","is-referenced-by-count":0,"title":["Recent developments in Friedreich\u2019s ataxia: a state-of-the-art review"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6174-9435","authenticated-orcid":false,"given":"Laura R","family":"Chapman","sequence":"first","affiliation":[{"name":"Sheffield Institute for Translational Neuroscience , School of Medicine and Population Health, University of Sheffield, 385a Glossop Road, Sheffield, S10 2HQ ,","place":["UK"]},{"name":"Sheffield Children\u2019s Hospital Paediatrics Unit, , Clarkson Street , Sheffield, S10 2TH ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6439-0579","authenticated-orcid":false,"given":"Heather","family":"Mortiboys","sequence":"additional","affiliation":[{"name":"Sheffield Institute for Translational Neuroscience , School of Medicine and Population Health, University of Sheffield, 385a Glossop Road, Sheffield, S10 2HQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8925-2567","authenticated-orcid":false,"given":"Pamela J","family":"Shaw","sequence":"additional","affiliation":[{"name":"Sheffield Institute for Translational Neuroscience , School of Medicine and Population Health, University of Sheffield, 385a Glossop Road, Sheffield, S10 2HQ ,","place":["UK"]},{"name":"NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust , Sheffield, S10 2JF ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"2026051723463703800_fcag143-B1","author":"NORD"},{"key":"2026051723463703800_fcag143-B2","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104606","article-title":"Friedreich ataxia- pathogenesis and implications for therapies","volume":"132","author":"Delatycki","year":"2019","journal-title":"Neurobiol Dis"},{"key":"2026051723463703800_fcag143-B3","first-page":"online only","volume-title":"Gene reviews","author":"Bidichandani","year":"1993\u20132025"},{"key":"2026051723463703800_fcag143-B4"},{"key":"2026051723463703800_fcag143-B5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/archneur.59.5.743","article-title":"Friedreich ataxia: Effects of genetic understanding on clinical evaluation and therapy","volume":"59","author":"Lynch","year":"2002","journal-title":"Arch Neurol"},{"issue":"12","key":"2026051723463703800_fcag143-B6","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/120.12.2131","article-title":"Friedreich\u2019s ataxia. Revision of the phenotype according to molecular genetics","volume":"120","author":"Sch\u00f6ls","year":"1997","journal-title":"Brain"},{"issue":"5","key":"2026051723463703800_fcag143-B7","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ana.410410518","article-title":"Phenotypic variability in Friedreich ataxia: Role of the associated GAA triplet repeat expansion","volume":"41","author":"Montermini","year":"1997","journal-title":"Ann Neurol"},{"issue":"16","key":"2026051723463703800_fcag143-B8","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJM199610173351601","article-title":"Clinical and genetic abnormalities in patients with Friedreich\u2019s ataxia","volume":"335","author":"D\u00fcrr","year":"1996","journal-title":"N Engl J Med"},{"issue":"1","key":"2026051723463703800_fcag143-B9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1086\/513887","article-title":"Phenotype correlation and intergenerational dynamics of the Friedreich ataxia GAA trinucleotide repeat","volume":"61","author":"Monr\u00f3s","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"2","key":"2026051723463703800_fcag143-B10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1212\/01.WNL.0000073537.08141.77","article-title":"GAA expansion size and age at onset of Friedreich\u2019s ataxia","volume":"61","author":"Mateo","year":"2003","journal-title":"Neurology"},{"key":"2026051723463703800_fcag143-B11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","article-title":"Mortality in Friedreich ataxia","volume":"307","author":"Tsou","year":"2011","journal-title":"J Neurol Sci"},{"key":"2026051723463703800_fcag143-B12","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich\u2019s ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion","volume":"271","author":"Campuzano","year":"1996","journal-title":"Science"},{"key":"2026051723463703800_fcag143-B13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/1531-8249(199902)45:2<200::AID-ANA10>3.0.CO;2-U","article-title":"Friedreich\u2019s ataxia: Point mutations and clinical presentation of compound heterozygotes","volume":"45","author":"Coss\u00e9e","year":"1999","journal-title":"Ann Neurol"},{"issue":"11","key":"2026051723463703800_fcag143-B14","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/hmg\/6.11.1771","article-title":"Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes","volume":"6","author":"Campuzano","year":"1997","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2026051723463703800_fcag143-B15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.abb.2006.09.010","article-title":"Frataxin knockdown causes loss of cytoplasmic iron\u2013sulfur cluster functions, redox alterations and induction of heme transcripts","volume":"457","author":"Lu","year":"2007","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"2026051723463703800_fcag143-B16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41536-020-00107-x","article-title":"Mitochondrial dysfunction in neurological disorders: Exploring mitochondrial transplantation","volume":"5","author":"Norat","year":"2020","journal-title":"NPJ Regen Med"},{"key":"2026051723463703800_fcag143-B17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/jnc.12303","article-title":"Mitochondrial pathophysiology in Friedreich\u2019s ataxia","volume":"126","author":"Gonz\u00e1lez-Cabo","year":"2013","journal-title":"J Neurochem"},{"key":"2026051723463703800_fcag143-B18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev-biochem-013118-111540","article-title":"Mechanisms of mitochondrial iron-sulfur protein biogenesis","volume":"89","author":"Lill","year":"2020","journal-title":"Annu Rev Biochem"},{"issue":"22","key":"2026051723463703800_fcag143-B19","doi-asserted-by":"crossref","first-page":"12239","DOI":"10.1073\/pnas.220403797","article-title":"Frataxin activates mitochondrial energy conversion and oxidative phosphorylation","volume":"97","author":"Ristow","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2026051723463703800_fcag143-B20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1023\/A:1015629912477","article-title":"Primary and secondary defects of the mitochondrial respiratory chain","volume":"25","author":"Schapira","year":"2002","journal-title":"J Inherit Metab Dis"},{"issue":"15","key":"2026051723463703800_fcag143-B21","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/hmg\/ddi214","article-title":"Frataxin interacts functionally with mitochondrial electron transport chain proteins","volume":"14","author":"Gonz\u00e1lez-Cabo","year":"2005","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2026051723463703800_fcag143-B22","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1096\/fj.05-4212fje","article-title":"Reduction of Caenorhabditis elegans frataxin increases sensitivity to oxidative stress, reduces lifespan, and causes lethality in a mitochondrial complex II mutant","volume":"20","author":"V\u00e1zquez-Manrique","year":"2006","journal-title":"FASEB J."},{"issue":"1","key":"2026051723463703800_fcag143-B23","doi-asserted-by":"crossref","first-page":"C22","DOI":"10.1152\/ajpcell.00194.2006","article-title":"Human NADH:ubiquinone oxidoreductase deficiency: Radical changes in mitochondrial morphology?","volume":"293","author":"Koopman","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"issue":"2","key":"2026051723463703800_fcag143-B24","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.bbrc.2012.01.022","article-title":"Oxidative stress induces mitochondrial fragmentation in frataxin-deficient cells","volume":"418","author":"Lefevre","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"2026051723463703800_fcag143-B25","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"2026051723463703800_fcag143-B26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13023-020-01475-9","article-title":"Onset features and time to diagnosis in Friedreich\u2019s ataxia","volume":"15","author":"Indelicato","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"2026051723463703800_fcag143-B27","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1136\/jnnp.2003.028605","article-title":"Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers","volume":"75","author":"Pianese","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2026051723463703800_fcag143-B28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1086\/301680","article-title":"The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure","volume":"62","author":"Bidichandani","year":"1998","journal-title":"Am J Hum Genet"},{"issue":"6","key":"2026051723463703800_fcag143-B29","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1096\/fj.07-097857","article-title":"DNA triplexes and Friedreich ataxia","volume":"22","author":"Wells","year":"2008","journal-title":"FASEB J."},{"key":"2026051723463703800_fcag143-B30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1097-2765(00)80474-8","article-title":"Sticky DNA: Self-association properties of long GAA\u00b7TTC repeats in R\u00b7R\u00b7Y triplex structures from Friedreich\u2019s ataxia","volume":"3","author":"Sakamoto","year":"1999","journal-title":"Mol Cell"},{"issue":"5","key":"2026051723463703800_fcag143-B31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004318","article-title":"R-loops associated with triplet repeat expansions promote gene silencing in Friedreich ataxia and fragile X syndrome","volume":"10","author":"Groh","year":"2014","journal-title":"PLoS Genet"},{"issue":"22","key":"2026051723463703800_fcag143-B32","doi-asserted-by":"crossref","first-page":"15194","DOI":"10.1074\/jbc.M114.566414","article-title":"Altered nucleosome positioning at the transcription start site and deficient transcriptional initiation in Friedreich ataxia","volume":"289","author":"Chutake","year":"2014","journal-title":"J Biol Chem."},{"issue":"6","key":"2026051723463703800_fcag143-B33","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1074\/jbc.M110.194035","article-title":"Repeat expansion affects both transcription initiation and elongation in Friedreich ataxia cells","volume":"286","author":"Kumari","year":"2011","journal-title":"J Biol Chem."},{"issue":"4","key":"2026051723463703800_fcag143-B34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ana.24260","article-title":"Epigenetic therapy for Friedreich ataxia","volume":"76","author":"Soragni","year":"2014","journal-title":"Ann Neurol"},{"issue":"31","key":"2026051723463703800_fcag143-B35","doi-asserted-by":"crossref","first-page":"11497","DOI":"10.1073\/pnas.0604939103","article-title":"DNA sequence-specific polyamides alleviate transcription inhibition associated with long GAA\u00b7TTC repeats in Friedreich\u2019s ataxia","volume":"103","author":"Burnett","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2026051723463703800_fcag143-B36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/84818","article-title":"Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits","volume":"27","author":"Puccio","year":"2001","journal-title":"Nat Genet"},{"issue":"11","key":"2026051723463703800_fcag143-B37","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1242\/dmm.030502","article-title":"Early cerebellar deficits in mitochondrial biogenesis and respiratory chain complexes in the KIKO mouse model of Friedreich ataxia","volume":"10","author":"Lin","year":"2017","journal-title":"Dis Model Mech."},{"issue":"3","key":"2026051723463703800_fcag143-B38","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.755","article-title":"Drp1-dependent peptide reverse mitochondrial fragmentation, a homeostatic response in Friedreich ataxia","volume":"9","author":"Johnson","year":"2021","journal-title":"Pharmacol Res Perspect"},{"issue":"38","key":"2026051723463703800_fcag143-B39","doi-asserted-by":"crossref","first-page":"16381","DOI":"10.1073\/pnas.0906784106","article-title":"Elucidation of the mechanism of mitochondrial iron loading in Friedreich\u2019s ataxia by analysis of a mouse mutant","volume":"106","author":"Huang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026051723463703800_fcag143-B40","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103339","article-title":"Deciphering the ferroptosis pathways in dorsal root ganglia of Friedreich ataxia models. The role of LKB1\/AMPK, KEAP1, and GSK3\u03b2 in the impairment of the NRF2 response","volume":"76","author":"Sanz-Alc\u00e1zar","year":"2024","journal-title":"Redox Biol"},{"key":"2026051723463703800_fcag143-B41","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101790","article-title":"Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities","volume":"83","author":"Soares","year":"2023","journal-title":"Ageing Res Rev"},{"issue":"23","key":"2026051723463703800_fcag143-B42","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1093\/hmg\/ddh324","article-title":"Iron-sulfur protein maturation in human cells: Evidence for a function of frataxin","volume":"13","author":"Stehling","year":"2004","journal-title":"Hum Mol Genet"},{"issue":"1\u20132","key":"2026051723463703800_fcag143-B43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2011.01.010","article-title":"Friedreich\u2019s ataxia: Pathology, pathogenesis, and molecular genetics","volume":"303","author":"Koeppen","year":"2011","journal-title":"J Neurol Sci"},{"issue":"2","key":"2026051723463703800_fcag143-B44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/ng1097-215","article-title":"Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia","volume":"17","author":"Rotig","year":"1997","journal-title":"Nat Genet"},{"issue":"29","key":"2026051723463703800_fcag143-B45","doi-asserted-by":"crossref","first-page":"18389","DOI":"10.1074\/jbc.273.29.18389","article-title":"Mt-Hsp70 homolog, Ssc2p, required for maturation of yeast frataxin and mitochondrial iron homeostasis","volume":"273","author":"Knight","year":"1998","journal-title":"J Biol Chem"},{"issue":"24","key":"2026051723463703800_fcag143-B46","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1093\/hmg\/ddg349","article-title":"Reduction in frataxin causes progressive accumulation of mitochondrial damage","volume":"12","author":"Karthikeyan","year":"2003","journal-title":"Hum Mol Genet"},{"issue":"46","key":"2026051723463703800_fcag143-B47","doi-asserted-by":"crossref","first-page":"33025","DOI":"10.1074\/jbc.274.46.33025","article-title":"Yeast mitochondrial protein, Nfs1p, coordinately regulates iron-sulfur cluster proteins, cellular iron uptake, and iron distribution","volume":"274","author":"Li","year":"1999","journal-title":"J Biol Chem"},{"issue":"9","key":"2026051723463703800_fcag143-B48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184961","article-title":"SAXS and stability studies of iron-induced oligomers of bacterial frataxin CyaY","volume":"12","author":"Fekry","journal-title":"PLoS One"},{"issue":"28","key":"2026051723463703800_fcag143-B49","doi-asserted-by":"crossref","first-page":"9757","DOI":"10.1073\/pnas.0804261105","article-title":"The MCK mouse heart model of Friedreich\u2019s ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation","volume":"105","author":"Whitnall","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026051723463703800_fcag143-B50","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2006-12-065433","article-title":"Selective iron chelation in Friedreich ataxia: Biologic and clinical implications","volume":"110","author":"Boddaert","year":"2007","journal-title":"Blood"},{"issue":"50","key":"2026051723463703800_fcag143-B51","doi-asserted-by":"crossref","first-page":"20590","DOI":"10.1073\/pnas.1215349109","article-title":"Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia","volume":"109","author":"Whitnall","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2026051723463703800_fcag143-B52","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/mus.26610","article-title":"Open-label pilot study of oral methylprednisolone for the treatment of patients with Friedreich ataxia","volume":"60","author":"Patel","year":"2019","journal-title":"Muscle Nerve"},{"issue":"12","key":"2026051723463703800_fcag143-B53","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.3390\/ijms23126735","article-title":"Deferiprone: A forty-year-old multi-targeting drug with possible activity against COVID-19 and diseases of similar symptomatology","volume":"23","author":"Kontoghiorghes","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2026051723463703800_fcag143-B54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1086\/321283","article-title":"Friedreich ataxia: From GAA triplet-repeat expansion to frataxin deficiency","volume":"69","author":"Patel","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"9","key":"2026051723463703800_fcag143-B55","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1161\/01.CIR.95.9.2247","article-title":"Correlation between left ventricular hypertrophy and GAA trinucleotide repeat length in Friedreich\u2019s ataxia","volume":"95","author":"Isnard","year":"1997","journal-title":"Circulation"},{"issue":"7","key":"2026051723463703800_fcag143-B56","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/mds.22864","article-title":"Analysis of the factors influencing the cardiac phenotype in Friedreich\u2019s ataxia","volume":"25","author":"Rajagopalan","year":"2010","journal-title":"Mov Disord."},{"issue":"12","key":"2026051723463703800_fcag143-B57","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jacbts.2022.04.005","article-title":"Cardiovascular research in Friedreich ataxia: Unmet needs and opportunities","volume":"7","author":"Payne","year":"2022","journal-title":"JACC Basic Transl Sci"},{"issue":"20","key":"2026051723463703800_fcag143-B58","doi-asserted-by":"crossref","first-page":"13291","DOI":"10.1074\/jbc.R900010200","article-title":"The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress","volume":"284","author":"Nguyen","year":"2009","journal-title":"J Biol Chem."},{"key":"2026051723463703800_fcag143-B59","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.freeradbiomed.2013.02.008","article-title":"Regulation of Nrf2\u2014An update","volume":"66","author":"Niture","year":"2014","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"2026051723463703800_fcag143-B60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000812","article-title":"Altered gene expression and DNA damage in peripheral blood cells from Friedreich\u2019s ataxia patients: Cellular model of pathology","volume":"6","author":"Haugen","year":"2010","journal-title":"PLoS Genet"},{"issue":"1","key":"2026051723463703800_fcag143-B61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004253","article-title":"Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia","volume":"4","author":"Paupe","year":"2009","journal-title":"PLoS One"},{"issue":"3","key":"2026051723463703800_fcag143-B62","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/acn3.731","article-title":"Randomized, double-blind, placebo-controlled study of interferon-\u03b3 1b in Friedreich ataxia","volume":"6","author":"Lynch","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"2026051723463703800_fcag143-B63","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/152308602753666307","article-title":"Activation of the mouse heme oxygenase-1 gene by 15-deoxy-\u039412, 14-prostaglandin J2 is mediated by the stress response elements and transcription factor Nrf2","volume":"4","author":"Gong","year":"2002","journal-title":"Antioxid Redox Signal"},{"key":"2026051723463703800_fcag143-B64","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.abb.2016.08.005","article-title":"Keap1, the cysteine-based mammalian intracellular sensor for electrophiles and oxidants","volume":"617","author":"Dinkova-Kostova","year":"2017","journal-title":"Arch Biochem Biophys"},{"issue":"8","key":"2026051723463703800_fcag143-B65","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1128\/MCB.26.8.2887-2900.2006","article-title":"Keap1 recruits Neh2 through binding to ETGE and DLG motifs: Characterization of the two-site molecular recognition model","volume":"26","author":"Tong","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2026051723463703800_fcag143-B66","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00204-011-0674-5","article-title":"The cytoprotective role of the Keap1-Nrf2 pathway","volume":"85","author":"Baird","year":"2011","journal-title":"Arch Toxicol"},{"issue":"34","key":"2026051723463703800_fcag143-B67","doi-asserted-by":"crossref","first-page":"24756","DOI":"10.1074\/jbc.M601119200","article-title":"Dimerization of substrate adaptors can facilitate Cullin-mediated ubiquitylation of proteins by a \u201ctethering\u201d mechanism: A two-site interaction model for the Nrf2-Keap1 complex","volume":"281","author":"McMahon","year":"2006","journal-title":"J Biol Chem."},{"issue":"6","key":"2026051723463703800_fcag143-B68","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1124\/mol.109.058453","article-title":"Nrf2 cysteine residues are critical for oxidant\/electrophile-sensing, Kelch-like ECH-associated protein-1-dependent ubiquitination-proteasomal degradation, and transcription activation","volume":"76","author":"He","year":"2009","journal-title":"Mol Pharmacol"},{"issue":"13","key":"2026051723463703800_fcag143-B69","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1089\/ars.2012.4537","article-title":"Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich\u2019s ataxia YG8R mouse model","volume":"19","author":"Shan","year":"2013","journal-title":"Antioxid Redox Signal"},{"issue":"4","key":"2026051723463703800_fcag143-B70","doi-asserted-by":"crossref","first-page":"7853","DOI":"10.3390\/ijms14047853","article-title":"Frataxin deficiency leads to reduced expression and impaired translocation of NF-E2-related factor (nrf2) in cultured motor neurons","volume":"14","author":"D\u2019Oria","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"43","key":"2026051723463703800_fcag143-B71","doi-asserted-by":"crossref","first-page":"42588","DOI":"10.1074\/jbc.M301872200","article-title":"Actin glutathionylation increases in fibroblasts of patients with Friedreich\u2019s ataxia: A potential role in the pathogenesis of the disease","volume":"278","author":"Pastore","year":"2003","journal-title":"J Biol Chem."},{"key":"2026051723463703800_fcag143-B72","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1558493","article-title":"Clinical and cognitive assessment in Friedreich ataxia clinical trials: A review","volume":"16","author":"Darriba","year":"2025","journal-title":"Front Neurol"},{"issue":"Suppl 1","key":"2026051723463703800_fcag143-B73","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/jnc.12318","article-title":"Monitoring progression in Friedreich ataxia (FRDA): The use of clinical scales","volume":"126","author":"B\u00fcrk","year":"2013","journal-title":"J Neurochem"},{"issue":"4","key":"2026051723463703800_fcag143-B74","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/jnnp.2006.096008","article-title":"How is disease progress in Friedreich\u2019s ataxia best measured? A study of four rating scales","volume":"78","author":"Fahey","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"2026051723463703800_fcag143-B75","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mds.22912","article-title":"Measuring the rate of progression in Friedreich ataxia: Implications for clinical trial design","volume":"25","author":"Friedman","year":"2010","journal-title":"Mov Disord"},{"issue":"2","key":"2026051723463703800_fcag143-B76","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s12311-011-0316-8","article-title":"Ataxia rating scales-psychometric profiles, natural history and their application in clinical trials","volume":"11","author":"Saute","year":"2012","journal-title":"Cerebellum"},{"issue":"11","key":"2026051723463703800_fcag143-B77","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1212\/01.wnl.0000218155.46739.90","article-title":"Measuring Friedreich ataxia: Complementary features of examination and performance measures","volume":"66","author":"Lynch","year":"2006","journal-title":"Neurology"},{"key":"2026051723463703800_fcag143-B78"},{"key":"2026051723463703800_fcag143-B79","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fncel.2018.00188","article-title":"Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich\u2019s ataxia models","volume":"12","author":"Abeti","year":"2018","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"2026051723463703800_fcag143-B80","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/acn3.660","article-title":"Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia","volume":"6","author":"Lynch","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"2026051723463703800_fcag143-B81","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study)","volume":"89","author":"Lynch","year":"2021","journal-title":"Ann Neurol"},{"issue":"1-2","key":"2026051723463703800_fcag143-B82","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jns.2007.10.008","article-title":"Antioxidant use in Friedreich ataxia","volume":"267","author":"Myers","year":"2008","journal-title":"J Neurol Sci"},{"issue":"Suppl 4","key":"2026051723463703800_fcag143-B83","doi-asserted-by":"crossref","first-page":"S683","DOI":"10.33549\/physiolres.934712","article-title":"Coenzyme Q10 effects in neurological diseases","volume":"70","author":"Rauchov\u00e1","year":"2021","journal-title":"Physiol Res"},{"issue":"1-2","key":"2026051723463703800_fcag143-B84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00744743","article-title":"New concepts on the role of ubiquinone in the mitochondrial respiratory chain","volume":"13","author":"Trumpower","year":"1981","journal-title":"J Bioenerg Biomembr"},{"issue":"5","key":"2026051723463703800_fcag143-B85","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ana.1001","article-title":"Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich\u2019s ataxia","volume":"49","author":"Lodi","year":"2001","journal-title":"Ann Neurol"},{"issue":"4","key":"2026051723463703800_fcag143-B86","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/archneur.62.4.621","article-title":"Antioxidant treatment of patients with Friedreich ataxia: Four-year follow-up","volume":"62","author":"Hart","year":"2005","journal-title":"Arch Neurol"},{"issue":"12","key":"2026051723463703800_fcag143-B87","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1468-1331.2008.02318.x","article-title":"Coenzyme Q10 and vitamin E deficiency in Friedreich\u2019s ataxia: Predictor of efficacy of vitamin e and coenzyme Q10 therapy","volume":"15","author":"Cooper","year":"2008","journal-title":"Eur J Neurol"},{"issue":"1","key":"2026051723463703800_fcag143-B88","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0014-5793(85)80650-5","article-title":"Stimulation of the respiratory and phosphorylating activities in rat brain mitochondria by idebenone (CV-2619), a new agent improving cerebral metabolism","volume":"184","author":"Sugiyama","year":"1985","journal-title":"FEBS Lett"},{"issue":"10","key":"2026051723463703800_fcag143-B89","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S1474-4422(07)70220-X","article-title":"Neurological effects of high-dose idebenone in patients with Friedreich\u2019s ataxia: A randomised, placebo-controlled trial","volume":"6","author":"Di Prospero","year":"2007","journal-title":"Lancet Neurol."},{"issue":"8","key":"2026051723463703800_fcag143-B90","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archneurol.2010.168","article-title":"A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia","volume":"67","author":"Lynch","year":"2010","journal-title":"Arch Neurol"},{"issue":"4","key":"2026051723463703800_fcag143-B91","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/heart.87.4.346","article-title":"Idebenone and reduced cardiac hypertrophy in Friedreich\u2019s ataxia","volume":"87","author":"Hausse","year":"2002","journal-title":"Heart"},{"issue":"2","key":"2026051723463703800_fcag143-B92","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ahj.2010.10.038","article-title":"Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA)","volume":"161","author":"Lagedrost","year":"2011","journal-title":"Am Heart J"},{"issue":"3","key":"2026051723463703800_fcag143-B93","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/biomedicines6030091","article-title":"Resveratrol: A double-edged sword in health benefits","volume":"6","author":"Salehi","year":"2018","journal-title":"Biomedicines"},{"issue":"6","key":"2026051723463703800_fcag143-B94","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bbadis.2014.09.011","article-title":"Neuroprotective action of resveratrol","volume":"1852","author":"Bastianetto","year":"2015","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2026051723463703800_fcag143-B95","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/392169","article-title":"Resveratrol: A focus on several neurodegenerative diseases","volume":"2015","author":"Tellone","year":"2015","journal-title":"Oxid Med Cell Longev"},{"issue":"2-3","key":"2026051723463703800_fcag143-B96","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12035-010-8111-y","article-title":"Resveratrol as a therapeutic agent for neurodegenerative diseases","volume":"41","author":"Sun","year":"2010","journal-title":"Mol Neurobiol."},{"issue":"5","key":"2026051723463703800_fcag143-B97","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1007\/s00415-015-7719-2","article-title":"An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels","volume":"262","author":"Yiu","year":"2015","journal-title":"J Neurol"},{"issue":"8","key":"2026051723463703800_fcag143-B98","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1177\/0883073816636087","article-title":"Clinical experience with deferiprone treatment for Friedreich ataxia","volume":"31","author":"Elincx-Benizri","year":"2016","journal-title":"J Child Neurol"},{"issue":"4","key":"2026051723463703800_fcag143-B99","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ana.24248","article-title":"Deferiprone in Friedreich ataxia: A 6-month randomized controlled trial","volume":"76","author":"Pandolfo","year":"2014","journal-title":"Ann Neurol"},{"issue":"7","key":"2026051723463703800_fcag143-B100","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.25836","article-title":"Safety and tolerability of carbamylated erythropoietin in Friedreich\u2019s ataxia","volume":"29","author":"Boesch","year":"2014","journal-title":"Mov Disord."},{"issue":"13","key":"2026051723463703800_fcag143-B101","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/mds.22294","article-title":"Neurological effects of recombinant human erythropoietin in Friedreich\u2019s ataxia: A clinical pilot trial","volume":"23","author":"Boesch","year":"2008","journal-title":"Mov Disord."},{"issue":"5","key":"2026051723463703800_fcag143-B102","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/jon.12050","article-title":"White matter changes in patients with Friedreich ataxia after treatment with erythropoietin","volume":"24","author":"Egger","year":"2014","journal-title":"J Neuroimaging."},{"issue":"7","key":"2026051723463703800_fcag143-B103","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069229","article-title":"Bioenergetics of the calf muscle in Friedreich ataxia patients measured by 31P-MRS before and after treatment with recombinant human erythropoietin","volume":"8","author":"Nachbauer","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"2026051723463703800_fcag143-B104","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s12311-011-0287-9","article-title":"Effects of erythropoietin on frataxin levels and mitochondrial function in Friedreich ataxia\u2014A dose-response trial","volume":"10","author":"Nachbauer","year":"2011","journal-title":"Cerebellum"},{"issue":"5","key":"2026051723463703800_fcag143-B105","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ana.21177","article-title":"Friedreich\u2019s ataxia: Clinical pilot trial with recombinant human erythropoietin","volume":"62","author":"Boesch","year":"2007","journal-title":"Ann Neurol"},{"issue":"13","key":"2026051723463703800_fcag143-B106","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1093\/hmg\/dds110","article-title":"Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model","volume":"21","author":"Tomassini","year":"2012","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2026051723463703800_fcag143-B107","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ane.12337","article-title":"Open-label pilot study of interferon gamma-1b in Friedreich ataxia","volume":"132","author":"Seyer","year":"2015","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"2026051723463703800_fcag143-B108","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134221","article-title":"Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia","volume":"5","author":"Igoillo-Esteve","year":"2020","journal-title":"JCI Insight"},{"issue":"6","key":"2026051723463703800_fcag143-B109","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000200034","article-title":"Efficacy and safety of leriglitazone in patients with Friedreich ataxia: A phase 2 double-blind, randomized controlled trial (FRAMES)","volume":"8","author":"Pandolfo","year":"2022","journal-title":"Neurol Genet"},{"key":"2026051723463703800_fcag143-B110","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105162","article-title":"PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich ataxia","volume":"148","author":"Rodr\u00edguez-Pascau","year":"2021","journal-title":"Neurobiol Dis"},{"key":"2026051723463703800_fcag143-B111","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.atherosclerosis.2019.11.018","article-title":"Dietary linoleic acid and human health: Focus on cardiovascular and cardiometabolic effects","volume":"292","author":"Marangoni","year":"2020","journal-title":"Atherosclerosis"},{"issue":"3","key":"2026051723463703800_fcag143-B112","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00415-022-11501-4","article-title":"Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia","volume":"270","author":"Lynch","year":"2023","journal-title":"J Neurol"},{"issue":"3-5","key":"2026051723463703800_fcag143-B113","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.plefa.2008.09.003","article-title":"Regulation of brain polyunsaturated fatty acid uptake and turnover","volume":"79","author":"Chen","year":"2008","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"2","key":"2026051723463703800_fcag143-B114","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.toxlet.2011.07.020","article-title":"Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson\u2019s disease","volume":"207","author":"Shchepinov","year":"2011","journal-title":"Toxicol Lett"},{"issue":"23","key":"2026051723463703800_fcag143-B115","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1111\/febs.14291","article-title":"Deuterium-reinforced polyunsaturated fatty acids improve cognition in a mouse model of sporadic Alzheimer\u2019s disease","volume":"284","author":"Elharram","year":"2017","journal-title":"FEBS J."},{"issue":"16","key":"2026051723463703800_fcag143-B116","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1111\/febs.14590","article-title":"Deuterium-reinforced linoleic acid lowers lipid peroxidation and mitigates cognitive impairment in the Q140 knock in mouse model of Huntington\u2019s disease","volume":"285","author":"Hatami","year":"2018","journal-title":"FEBS J."},{"key":"2026051723463703800_fcag143-B117","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.freeradbiomed.2014.12.023","article-title":"Isotope-reinforced polyunsaturated fatty acids protect mitochondria from oxidative stress","volume":"82","author":"Andreyev","year":"2015","journal-title":"Free Radic Biol Med"},{"key":"2026051723463703800_fcag143-B118","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.phrs.2015.05.015","article-title":"Targeting lipid peroxidation and mitochondrial imbalance in Friedreich\u2019s ataxia","volume":"99","author":"Abeti","year":"2015","journal-title":"Pharmacol Res"},{"issue":"1","key":"2026051723463703800_fcag143-B119","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.redox.2013.06.004","article-title":"Insights into the role of oxidative stress in the pathology of Friedreich ataxia using peroxidation resistant polyunsaturated fatty acids","volume":"1","author":"Cotticelli","year":"2013","journal-title":"Redox Biol"},{"issue":"1","key":"2026051723463703800_fcag143-B120","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.freeradbiomed.2010.10.690","article-title":"Isotope-reinforced polyunsaturated fatty acids protect yeast cells from oxidative stress","volume":"50","author":"Hill","year":"2011","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"2026051723463703800_fcag143-B121","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.freeradbiomed.2012.06.004","article-title":"Small amounts of isotope-reinforced polyunsaturated fatty acids suppress lipid autoxidation","volume":"53","author":"Hill","year":"2012","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"2026051723463703800_fcag143-B122","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1017\/S0317167100043870","article-title":"Oral lecithin and linoleic acid in Friedreich\u2019s ataxia: II. Clinical results","volume":"9","author":"Melancon","year":"1982","journal-title":"Can J Neurol Sci"},{"issue":"6","key":"2026051723463703800_fcag143-B123","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/acn3.51373","article-title":"Results of a randomized double-blind study evaluating luvadaxistat in adults with Friedreich ataxia","volume":"8","author":"Wang","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"2026051723463703800_fcag143-B124","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/archneur.1995.00540290037015","article-title":"Double-blind crossover study with levorotatory form of hydroxytryptophan in patients with degenerative cerebellar diseases","volume":"52","author":"Wessel","year":"1995","journal-title":"Arch Neurol"},{"issue":"5","key":"2026051723463703800_fcag143-B125","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/archneur.1995.00540290042016","article-title":"Levorotatory form of 5-hydroxytryptophan in Friedreich\u2019s ataxia: Results of a double-blind drug-placebo cooperative study","volume":"52","author":"Trouillas","year":"1995","journal-title":"Arch Neurol"},{"issue":"6271","key":"2026051723463703800_fcag143-B126","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1136\/bmj.282.6271.1197","article-title":"Lecithin treatment in Friedreich\u2019s ataxia","volume":"282","author":"Pentland","year":"1981","journal-title":"Br Med J"},{"key":"2026051723463703800_fcag143-B127","author":"Evrysdi"},{"issue":"4","key":"2026051723463703800_fcag143-B128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tips.2019.02.001","article-title":"Therapeutic prospects for Friedreich\u2019s ataxia","volume":"40","author":"Zhang","year":"2019","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"2026051723463703800_fcag143-B129","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101193","article-title":"AAV8 gene therapy reverses cardiac pathology and prevents early mortality in a mouse model of Friedreich\u2019s ataxia","volume":"32","author":"Chang","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026051723463703800_fcag143-B130","author":"Friedreich\u2019s Ataxia Research Alliance"},{"issue":"3","key":"2026051723463703800_fcag143-B131","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/hum.2006.178","article-title":"Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain","volume":"18","author":"Taymans","year":"2007","journal-title":"Hum Gene Ther"},{"key":"2026051723463703800_fcag143-B132","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.omtm.2020.08.018","article-title":"High levels of frataxin overexpression lead to mitochondrial and cardiac toxicity in mouse models","volume":"19","author":"Belbellaa","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8","key":"2026051723463703800_fcag143-B133","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.ymthe.2018.05.006","article-title":"Rapid and complete reversal of sensory ataxia by gene therapy in a novel model of Friedreich ataxia","volume":"26","author":"Piguet","year":"2018","journal-title":"Mol Ther"},{"issue":"5","key":"2026051723463703800_fcag143-B134","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nm.3510","article-title":"Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich\u2019s ataxia","volume":"20","author":"Perdomini","year":"2014","journal-title":"Nat Med"},{"issue":"8","key":"2026051723463703800_fcag143-B135","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/hmg\/ddy427","article-title":"Correction of half the cardiomyocytes fully rescue Friedreich ataxia mitochondrial cardiomyopathy through cell-autonomous mechanisms","volume":"28","author":"Belbellaa","year":"2019","journal-title":"Hum Mol Genet"},{"key":"2026051723463703800_fcag143-B136"},{"key":"2026051723463703800_fcag143-B137"},{"issue":"5","key":"2026051723463703800_fcag143-B138","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/gt.2016.89","article-title":"Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia","volume":"24","author":"Ouellet","year":"2017","journal-title":"Gene Ther"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcag143\/68117747\/fcag143.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/3\/fcag143\/68117747\/fcag143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/3\/fcag143\/68117747\/fcag143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T03:46:59Z","timestamp":1779076019000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcag143\/8659495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":138,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcag143","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"fcag143"}}